Record Revenue Growth
Achieved total revenue of $136 million, reflecting a 17% year-over-year increase. This growth was broad-based across all franchises.
Strong Performance in Appendage Management
Worldwide revenue for appendage management grew over 20%, driven by open left atrial appendage management growth of 29%.
Pain Management Franchise Expansion
Pain Management grew nearly 43% in the quarter, driven by sales of cryoSPHERE MAX and cryoSPHERE+ probes.
Completion of LeAAPS Clinical Trial Enrollment
Completed enrollment in the LeAAPS clinical trial, the largest global medical device clinical trial in cardiac surgery, with over 6,500 patients.
Positive Cash Generation
Generated nearly $18 million in cash during the second quarter, ending with $117.8 million in cash and investments.